Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection

Experimental Parasitology

Volumn 131, Issue 3, 2012, Pages 317-324

  Daifalla, Nada S ^a   Bayih, Abebe Genetu ^a   Gedamu, Lashitew ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

CpG ODN; GLA; Leishmania; Superoxide dismutase; Vaccine

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; GLUCOPYRANOSYL LIPID A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; LEISHMANIA DONOVANI IRON SUPEROXIDE DISMUTASE B1 VACCINE; LEISHMANIA VACCINE; RECOMBINANT PROTEIN; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG FORMULATION; EXPERIMENTAL MOUSE; FOOT PAD; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOSTIMULATION; LEISHMANIA MAJOR; LEISHMANIASIS; LIMB SWELLING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; FEMALE; IMMUNE SERA; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-10; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; PROTOZOAN VACCINES; RANDOM ALLOCATION; RECOMBINANT PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS; SPLEEN; SUPEROXIDE DISMUTASE; TOLL-LIKE RECEPTORS; VACCINES, SYNTHETIC;

LEISHMANIA DONOVANI; LEISHMANIA MAJOR; MUS;

EID: 84862568334     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2012.05.002     Document Type: Article

References (48)

1. Ashford R.W. The leishmaniases as emerging and reemerging zoonoses. Int. J. Parasitol. 2000, 30(12-13):1269-1281.
2. Badiee A., Jaafari M.R., Samiei A., Soroush D., Khamesipour A. Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice. Clin. Vaccine Immunol. 2008, 15(4):668-674.
3. Baldwin S.L., Bertholet S., Kahn M., Zharkikh I., Ireton G.C., Vedvick T.S., Reed S.G., Coler R.N. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 2009, 27(23):3063-3071.
4. Baldwin S.L., Shaverdian N., Goto Y., Duthie M.S., Raman V.S., Evers T., Mompoint F., Vedvick T.S., Bertholet S., Coler R.N., Reed S.G. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009, 27(43):5956-5963.
5. Bern C., Maguire J.H., Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Neglected Trop. Diseases 2008, 2(10):e313.
6. Bertholet S., Goto Y., Carter L., Bhatia A., Howard R.F., Carter D., Coler R.N., Vedvick T.S., Reed S.G. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 2009, 27(50):7036-7045.
7. Coffman R.L. Mechanisms of helper T-cell regulation of B-cell activity. Ann. NY Acad. Sci. 1993, 681:25-28.
8. Croft S.L., Sundar S., Fairlamb A.H. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 2006, 19(1):111-126.
9. Daifalla N.S., Genetu Bayih A., Gedamu L. Immunogenicity ofLeishmania donovani iron superoxide dismutase B1 and peroxidoxin 4 in BALB/c mice: the contribution of Toll-like receptor agonists as adjuvant. J. Exp. Parasitol. 2011, 129(3):292-298.
10. Datta N., Mukherjee S., Das L., Das P.K. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation. Eur. J. Immunol. 2003, 33(6):1508-1518.
11. Desjeux P. Human leishmaniases: epidemiology and public health aspects. World Health Stat. Q. 1992, 45(2-3):267-275.
12. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans. R. Soc. Trop. Med. Hyg. 2001, 95(3):239-243.
13. Handman E. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 2001, 14(2):229-243.
14. He Y., Vemulapalli R., Schurig G.G. Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu, Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type. Infect. Immun. 2002, 70(5):2535-2543.
15. Herwaldt B.L. Leishmaniasis. Lancet 1999, 354(9185):1191-1199.
16. Iborra S., Parody N., Abanades D.R., Bonay P., Prates D., Novais F.O., Barral-Netto M., Alonso C., Soto M. Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice. Microbes Infect. 2008, 10(10-11):1133-1141.
17. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004, 5(10):987-995.
18. Jaafari M.R., Badiee A., Khamesipour A., Samiei A., Soroush D., Kheiri M.T., Barkhordari F., McMaster W.R., Mahboudi F. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine 2007, 25(32):6107-6117.
19. Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Curr. Opin. Immunol. 2007, 19(1):39-45.
20. Kedzierski L., Zhu Y., Handman E. Leishmania vaccines: progress and problems. Parasitology 2006, 133(Suppl.):S87-S112.
21. LoVerde P.T., Carvalho-Queiroz C., Cook R. Vaccination with antioxidant enzymes confers protective immunity against challenge infection with Schistosoma mansoni. Memórias do Instituto Oswaldo Cruz 2004, 99(5 Suppl. 1):37-43.
22. Miles S.A., Conrad S.M., Alves R.G., Jeronimo S.M., Mosser D.M. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J. Exp. Med. 2005, 201(5):747-754.
23. Munoz-Montesino C., Andrews E., Rivers R., Gonzalez-Smith A., Moraga-Cid G., Folch H., Cespedes S., Onate A.A. Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells. Infect. Immun. 2004, 72(4):2081-2087.
24. Mutwiri G., Benjamin P., Soita H., Babiuk L.A. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen. Vaccine 2008, 26(22):2680-2688.
25. Muzio M., Mantovani A. Toll-like receptors (TLRs) signalling and expression pattern. J. Endotoxin Res. 2001, 7(4):297-300.
26. Muzio M., Polentarutti N., Bosisio D., Prahladan M.K., Mantovani A. Toll-like receptors: a growing family of immune receptors that are differentially expressed and regulated by different leukocytes. J. Leukoc. Biol. 2000, 67(4):450-456.
27. Paramchuk W.J., Ismail S.O., Bhatia A., Gedamu L. Cloning, characterization and overexpression of two iron superoxide dismutase cDNAs from Leishmania chagasi: role in pathogenesis. Mol. Biochem. Parasitol. 1997, 90(1):203-221.
28. Park S.U., Kathaperumal K., McDonough S., Akey B., Huntley J., Bannantine J.P., Chang Y.F. Immunization with a DNA vaccine cocktail induces a Th1 response and protects mice against Mycobacterium avium subsp. paratuberculosis challenge. Vaccine 2008, 26(34):4329-4337.
29. Pearson R.D., Sousa A.Q. Clinical spectrum of Leishmaniasis. Clin. Infect. Dis. 1996, 22(1):1-13.
30. Persing D.H., Coler R.N., Lacy M.J., Johnson D.A., Baldridge J.R., Hershberg R.M., Reed S.G. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 2002, 10(10 Suppl.):S32-S37.
31. Plewes K.A., Barr S.D., Gedamu L. Iron superoxide dismutases targeted to the glycosomes of Leishmania chagasi are important for survival. Infect. Immun. 2003, 71(10):5910-5920.
32. Raman V.S., Bhatia A., Picone A., Whittle J., Bailor H.R., O'Donnell J., Pattabhi S., Guderian J.A., Mohamath R., Duthie M.S., Reed S.G. Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J. Immunol. 2010, 185(3):1701-1710.
33. Raman V.S., O'Donnell J., Bailor H.R., Goto W., Lahiri R., Gillis T.P., Reed S.G., Duthie M.S. Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection. Infect. Immun. 2009, 77(12):5623-5630.
34. Ramirez L., Iborra S., Cortes J., Bonay P., Alonso C., Barral-Netto M., Soto M. BALB/c mice vaccinated with Leishmania major ribosomal proteins extracts combined with CpG oligodeoxynucleotides become resistant to disease caused by a secondary parasite challenge. J. Biomed. Biotechnol. 2010, 2010:1-9.
35. Reed S.G. Leishmaniasis vaccination: targeting the source of infection. J. Exp. Med. 2001, 194(3):F7-F9.
36. Reed S.G., Coler R.N., Campos-Neto A. Development of a leishmaniasis vaccine: the importance of MPL. Exp. Rev. Vaccines 2003, 2(2):239-252.
37. Sacks D., Anderson C. Re-examination of the immunosuppressive mechanisms mediating non-cure of Leishmania infection in mice. Immunol. Rev. 2004, 201:225-238.
38. Sacks D., Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2002, 2(11):845-858.
39. Shalaby K.A., Yin L., Thakur A., Christen L., Niles E.G., LoVerde P.T. Protection against Schistosoma mansoni utilizing DNA vaccination with genes encoding Cu/Zn cytosolic superoxide dismutase, signal peptide-containing superoxide dismutase and glutathione peroxidase enzymes. Vaccine 2003, 22(1):130-136.
40. Takeda K., Akira S. TLR signaling pathways. Semin. Immunol. 2004, 16(1):3-9.
41. Titus R.G., Marchand M., Boon T., Louis J.A. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol. 1985, 7(5):545-555.
42. Velez I.D., Gilchrist K., Martinez S., Ramirez-Pineda J.R., Ashman J.A., Alves F.P., Coler R.N., Bogatzki L.Y., Kahn S.J., Beckmann A.M., Cowgill K.D., Reed S.G., Piazza F.M. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 2009, 28(2):329-337.
43. Verthelyi D., Gursel M., Kenney R.T., Lifson J.D., Liu S., Mican J., Klinman D.M. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. J. Immunol. 2003, 170(9):4717-4723.
44. WHO, 2004. Scientific Work Group Report on Leishmaniasis. TDR/SWG/04. http://www.who.int/tdr.
45. WHO, 2002. The World Health Report 197-97 [online]. http://www.who.int.htm.
46. Yeganeh F., Barkhordari F., Omidi M., Samiei A., Adeli A., Mahboudi F., Kamali-Sarvestani E. Cloning and expression of Leishmania major superoxide dismutase B1: a potential target antigen for serodiagnosis of Leishmaniasis. Iranian J. Immunol. 2009, 6(3):130-140.
47. Zarember K.A., Godowski P.J. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 2002, 168(2):554-561.
48. Zimmermann S., Egeter O., Hausmann S., Lipford G.B., Rocken M., Wagner H., Heeg K. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J. Immunol. 1998, 160(8):3627-3630.